International journal of radiation oncology, biology, physics · 2024
Osteoradionecrosis in Pediatric Patients Treated with Proton Therapy for Head and Neck Malignancies.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Grippin Adam J, Kim Andrew, Liu Yufei, Copling Sage, Nalin Ansel P, Crabtree Katina, Cheng Hunter, Kui Naishu, Zhang Zhe, McAleer Mary Frances, Grosshans David, McGovern Susan, Sun Ryan, Paulino Arnold C
Аннотация
PURPOSE: Osteoradionecrosis (ORN) is a feared complication after head and neck (H/N) radiation, but the incidence and radiation therapy risk factors for ORN in children are unknown. In this retrospective analysis of a prospectively collected data set, we evaluated the incidence and factors associated with the development of ORN in children treated with proton therapy (PT) for H/N malignancies.
MATERIALS AND METHODS: We reviewed records from patients treated at a single institution between December 2006 and February 2020, including demographic data, tumor, treatment details, ORN occurrence, and dosimetry.
RESULTS: We identified 117 pediatric patients treated with PT for H/N malignancies. The most common histology was rhabdomyosarcoma (46%), and the most common involved sites were the parameningeal sites (44%) and the orbit (32%). The majority received passive scatter (n = 81, 69%) and the remainder intensity modulated PT (n = 36, 31%). Only 2 (1.7%) developed ORN. Both patients had previous dental work and high radiation doses to the affected bone. Patient 1 had a maximum and mean dose to the affected bone of 68 and 42 Gy, while patient 2 received 64.2 and 56.4 Gy, respectively.
CONCLUSIONS: ORN was uncommon in our large, single institution cohort, occurring in only 1.7% of pediatric patients treated with PT for H/N malignancies.
MATERIALS AND METHODS: We reviewed records from patients treated at a single institution between December 2006 and February 2020, including demographic data, tumor, treatment details, ORN occurrence, and dosimetry.
RESULTS: We identified 117 pediatric patients treated with PT for H/N malignancies. The most common histology was rhabdomyosarcoma (46%), and the most common involved sites were the parameningeal sites (44%) and the orbit (32%). The majority received passive scatter (n = 81, 69%) and the remainder intensity modulated PT (n = 36, 31%). Only 2 (1.7%) developed ORN. Both patients had previous dental work and high radiation doses to the affected bone. Patient 1 had a maximum and mean dose to the affected bone of 68 and 42 Gy, while patient 2 received 64.2 and 56.4 Gy, respectively.
CONCLUSIONS: ORN was uncommon in our large, single institution cohort, occurring in only 1.7% of pediatric patients treated with PT for H/N malignancies.